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Significance of this study
What is already known about this subject?
 ► Individuals with KCNJ11 PNDM can be successfully 
treated with high- dose sulfonylureas which maintain 
excellent glycemic control without causing severe 
hypoglycemia.
 ► Some individuals with sulfonylurea- treated KCNJ11 
PNDM report mild- moderate postprandial hypogly-
cemia, particularly after protein/fat- rich meals.
What are the new findings?
 ► Individuals with sulfonylurea- treated KCNJ11 perma-
nent neonatal diabetes mellitus (PNDM) exhibit high-
er glucose values in response to a carbohydrate meal 
than to a protein meal, and for both meals glucose 
levels are higher than controls without diabetes, who 
exhibit much more tightly regulated glucose levels re-
gardless of meal type.
 ► The more tightly regulated glucose levels in controls 
results from much higher insulin secretion in response 
to carbohydrate than to protein, whereas cases with 
sulfonylurea- treated KCNJ11 PNDM have similar insu-
lin levels in response to both meal types.
 ► The similar insulin secretion with the different meals 
in individuals with sulfonylurea- treated KCNJ11 PNDM 
suggests a relative inability to modulate insulin se-
cretion in response to both higher (carbohydrate) and 
lower (protein/fat) glucose levels, consistent with a de-
pendence on non- K
ATP pathways for insulin secretion.
AbStrAct
Objective Insulin secretion in sulfonylurea- treated 
KCNJ11 permanent neonatal diabetes mellitus (PNDM) 
is thought to be mediated predominantly through 
amplifying non- KATP- channel pathways such as incretins. 
Affected individuals report symptoms of postprandial 
hypoglycemia after eating protein/fat- rich foods. 
We aimed to assess the physiological response to 
carbohydrate and protein/fat in people with sulfonylurea- 
treated KCNJ11 PNDM.
Research design and methods 5 adults with 
sulfonylurea- treated KCNJ11 PNDM and five age, 
sex and body mass index- matched controls without 
diabetes had a high- carbohydrate and high- protein/
fat meal on two separate mornings. Insulin(i) and 
glucose(g) were measured at baseline then regularly 
over 4 hours after the meal. Total area under the curve 
(tAUC) for insulin and glucose was calculated over 
4 hours and compared between meals in controls and 
KCNJ11 cases.
Results In controls, glucose values after carbohydrate 
and protein/fat were similar (median glucose tAUC0- 4h21.4 
vs 19.7 mmol/L, p=0.08). In KCNJ11 cases glucose levels 
were higher after carbohydrate than after protein/fat 
(median glucose tAUC0- 4h58.1 vs 31.3 mmol/L, p=0.04). 
These different glycemic responses reflected different 
patterns of insulin secretion: in controls, insulin secretion 
was greatly increased after carbohydrate versus protein/
fat (median insulin tAUC0- 4h727 vs 335 pmol/L, p=0.04), 
but in KCNJ11 cases insulin secretion was similar after 
carbohydrate and protein/fat (median insulin tAUC0- 4h327 
vs 378 pmol/L, p=0.50).
Conclusions Individuals with sulfonylurea- treated 
KCNJ11 PNDM produce similar levels of insulin in 
response to both carbohydrate and protein/fat meals 
despite carbohydrate resulting in much higher glucose 
levels and protein/fat resulting in relatively low glucose 
levels. This suggests in an inability to modulate insulin 
secretion in response to glucose levels, consistent 
with a dependence on non- KATP pathways for insulin 
secretion.
Trial registration number NCT02921906.
InTROduCTIOn
Activating KCNJ11 mutations are the most 
common cause of permanent neonatal 
diabetes mellitus (PNDM), diagnosed in the 
first 6 months of life.1 KCNJ11 encodes Kir6.2, 
the pore- forming subunit of the ATP- sensitive 
potassium (KATP) channel that, in the beta cell, 
closes in response to metabolically generated 
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Table 1 Clinical characteristics of study participants. All continuous numerical data are presented as median (range) unless 
otherwise stated. In one patient who was taking gliclazide and not glibenclamide, dose was converted to glibenclamide 
equivalent using % maximum dose according to British National Formulary
Clinical feature KCNJ11 cases Non- diabetic controls P value
Age (years) 39.1 (24.4–41.0) 39.6 (24.2–41.8) 0.60
Sex, male (%) 1 (20) 1 (20) 1.00
BMI 22.9 (22.4–26.8) 24.6 (23.9–25.6) 0.60
Fasting glucose (mmol/mol) 10.1 (8.6–11.9) 5.3 (4.8–5.5) 0.009
KCNJ11 mutation 4 R201H, 1 R201C N/A N/A
SU dose (mg/kg/day glibenclamide) 0.28 (0.07–1.21) N/A N/A
HbA1c (%) 6.9 (6.5–7.9) N/A N/A
HbA1c (mmol/mol) 52 (48–63) N/A N/A
BMI, body mass index; N/A, not applicable; SU, sulfonylurea.
Significance of this study
How might these results change the focus of research or 
clinical practice?
 ► Individuals with sulfonylurea- treated KCNJ11 PNDM should avoid 
meals lacking carbohydrate or missing meals to mitgate the risk of 
postprandial hypolycemia.
 ► Future research in individuals with sulfonylurea- treated KCNJ11 
PNDM will focus on assessing glucagon secretion at low levels of 
glucose, the counter- regulatory response to hypoglycemia, and the 
effects of different doses and types of sulfonylurea on the physio-
logical response to different meals.
ATP, causing beta cell depolarization and insulin secre-
tion. The SUR1 subunit, encoded by the ABCC8 gene, 
further regulates KATP channel activity by opening the 
channel in response to Mg- ADP, preventing insulin 
release.2 KCNJ11 mutations impair the ATP sensitivity of 
pancreatic KATP channels rendering them unresponsive to 
rising blood glucose and the beta cell remains hyperpo-
larized,3 resulting in absolute insulin deficiency. Affected 
individuals required treatment with replacement doses of 
insulin until it was shown that sulfonylureas (SU) could 
bind and close pancreatic KATP channels resulting in beta 
cell depolarization and endogenous insulin secretion.4 
This allowed 90% of individuals with KCNJ11 PNDM 
to stop insulin injections completely gaining excellent 
metabolic control which is maintained long term.4 5
Severe hypoglycemia is rarely observed in SU- treated 
KCNJ11 PNDM.5 6 This is remarkable given that the doses 
of SU used in affected individuals are around 5–10 times 
those used to treat type 2 diabetes (T2D) and indicates 
that SU- stimulated KATP channel activity is regulated, 
at least in part, in the presence of KCNJ11 mutations. 
However, as these mutations prevent regulation by ATP, 
it has been suggested that non- KATP- channel- mediated 
amplifying pathways of insulin secretion (eg, incretin 
hormones) predominate over the classical ATP pathway.4 
This is supported by the very low levels of insulin secre-
tion observed after intravenous glucose in comparison 
to oral glucose or meals, in individuals with SU- treated 
KCNJ11 PNDM.4 The role of SUs is assumed to be largely 
permissive in allowing the beta cell to respond to non- 
KATP- channel- mediated amplifying pathways, as opposed 
to directly stimulatory.4
Anecdotal reports from patients with KCNJ11 PNDM 
have suggested mild to moderate hypoglycemia occurs 
after meals rich in protein/fat and lacking carbohy-
drate7 or meals smaller than usual in size.6 This may 
reflect an inability to moderate food- stimulated insulin 
secretion in the context of falling glucose after a low- 
carbohydrate meal; both GLP-1 and nutrient stimula-
tion of the beta cell may play a role, as fatty acids and 
amino acids can drive insulin secretion through ATP- 
independent as well as ATP- dependent pathways.8–11 
Similarly, KATP channels on pancreatic alpha cells
12 
and glucose- sensing neurons in the brain ventro-
medial hypothalamus13 are thought to play a role in 
counter- regulatory responses to hypoglycemia via 
ATP- dependent and independent mechanisms.14 15 SU 
inhibition and protein can both stimulate alpha cell 
depolarization and glucagon secretion in vitro.16 17 
However, counter- regulatory processes are complex and 
remain incompletely understood.
Despite its clinical importance in relation to dietary 
advice and hypoglycemia risk, no studies have inves-
tigated the impact of protein or other food types on 
insulin or glucagon secretion in SU- treated KCNJ11 
PNDM. We therefore aimed to assess the insulin, glucose 
and glucagon response to carbohydrate and protein/fat 
in people with KCNJ11 PNDM, and to compare this with 
the physiological response to the same food types in indi-
viduals without diabetes.
ReseaRCH desIgn and meTHOds
Participants
Five adults >18 years of age with SU- treated KCNJ11 
PNDM and five controls without diabetes matched 
for age, sex and body mass index participated in the 
study. Clinical characteristics of the study participants 
are shown in table 1. All measured characteristics were 
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similar between the groups except fasting glucose which 
was higher in cases.
experimental procedure
Participants attended the Exeter NIHR Clinical Research 
Facility and were given a high- carbohydrate breakfast 
(77 g carbohydrate, 9 g protein, 1 g fat, 371 calories) 
consisting of orange juice and white toast with jam, and 
a high- protein/fat breakfast (46 g protein, 18 g fat, 6 g 
carbohydrate, 369 calories) consisting of ham and cheese, 
on two separate mornings in a random order. Participants 
with KCNJ11 PNDM took their usual prescribed dose of 
SU (five on glibenclamide, one on gliclazide) with each 
breakfast. These individuals also took part in a third visit 
during which they did not have any breakfast but took 
their SU tablet as usual that morning.
Before each visit the participants fasted overnight for a 
minimum of 10 hours. Prior to breakfast an intravenous 
cannula was inserted and two baseline blood samples 
(−5, 0 min) were taken for measurement of insulin, 
glucose, and glucagon. Breakfast was provided, on 
visits 1 and 2, and participants were given 15 min to eat. 
Participants were also given a glass of water and 1000 mg 
paracetamol with the meal as a non- invasive measure 
of gastric emptying.11 Any food remaining after 15 min 
was removed and weighed. One control participant and 
one case did not finish the protein meal within 15 min 
(they ate 90% and 75% of the breakfast, respectively). 
All participants ate the full carbohydrate meal. Blood 
samples were taken at regular intervals after breakfast 
(every 15 min for the first hour then every half hour 
for the last 3 hours); they were immediately centrifuged 
and frozen at −80°C for later measurement of glucose, 
insulin, glucagon, and paracetamol levels. Participants 
were also screened at each time point for autonomic 
and neuroglycopenic symptoms of hypoglycemia using 
standard questions scored from 1 to 7 on a Likert scale 
as previously described.12 13 For the individuals with 
KCNJ11 PNDM, the third visit involved the same proce-
dure but without any food.
Biochemical analysis
All biochemical analyses were performed in the Royal 
Devon and Exeter NHS Foundation Trust Clinical Labo-
ratory. Serum glucose and paracetamol were analyzed 
on the 702 module of the Cobas 8000 analyzer, serum 
insulin was analyzed on the 602 module of the Cobas 
8000 analyzer, and serum glucagon was analyzed on the 
Dynex DS2 automated ELISA platform.
statistical analyses
Data were analyzed in Stata V.14.2 using non- parametric 
statistical methods; Wilcoxon signed- rank test for paired 
continuous data and Mann- Whitney test for unpaired 
continuous data (independent samples). For categor-
ical data, Fisher’s exact test was used for between- group 
comparisons. Total area under the curve over 4 hours 
(tAUC0- 4h) and incremental area under the curve 
(iAUC0- 4h) for insulin, glucagon and glucose were calcu-
lated using the trapezoidal rule. Values are reported as 
median (range) throughout unless stated otherwise.
glucose levels and hypoglycemia
Glucose trends after meals and responses to hypoglycemia 
questionnaires were described and glucose tAUC0- 4h and 
iAUC0- 4h were compared between meals in controls and 
KCNJ11 cases.
Postmeal insulin secretion
Insulin tAUC0- 4h and iAUC0- 4h were compared between 
meals in controls and KCNJ11 cases. As baseline glucose 
values were different between cases and controls (table 1, 
online supplementary figure S1), insulin was also adjusted 
for glucose by calculating the ratios of total AUC for 
insulin and glucose (insulin tAUC/glucose tAUC)0- 4h.
18
Postmeal glucagon secretion
Glucagon tAUC0- 4h and iAUC0- 4h were compared between 
different meals in controls and KCNJ11 cases.
gastric emptying
Maximum serum paracetamol concentration (pmax) and 
time to maximum concentration (tmax) were used to calcu-
late the emptying index (tmax / pmax), which was compared 
between different meals to check for differences in rates 
of gastric emptying as previously described.19 Parac-
etamol tAUC0- 4h was also compared between controls and 
KCNJ11 cases and between meals.
effect of su without food
To examine the effect of SU alone, the glucose, insulin 
and glucagon analyses were repeated in KCNJ11 cases 
after no food and compared with the responses to the 
carbohydrate and protein/fat meals.
data cleaning
In the process of data analysis, for glucagon values <1.5 
(limit of detection of the assay) a value of 1.4 was used. 
For paracetamol values <1.2 (limit of detection of the 
assay) a value of 1.1 was used. The baseline values for 
each analysis were an average of the minus-5- minute (−5 
min) and 0- minute (0 min) values; if the −5 min or 0 min 
baseline value was missing, the single remaining baseline 
value was used. Where a value at a single time point was 
missing, an average of the values at the time points either 
side was imputed. On the three occasions where a sample 
was delayed due to the participant requiring recannu-
lation, the result was allocated to the closest scheduled 
time point.
ResulTs
different glucose levels after protein/fat and carbohydrate in 
KCNJ11 cases versus controls
Glucose levels were higher in cases versus controls 
after both carbohydrate (glucose tAUC 58.1 (45.9–
62.0) mmol/L vs 21.4 (19.3–25.7) mmol/L, p=0.009) 
and protein/fat (glucose tAUC 31.3 (23.5–35.3) mmol/L 
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Figure 1 (A) Glucose total area under the curve (AUC) over 4 hours. Controls are shown in light gray (diamonds are individuals 
and lines are group medians). KCNJ11 cases are shown in dark gray (circles are individuals and lines are group medians). 
(B) Insulin total AUC over 4 hours. Controls are shown in light gray (diamonds are individuals and lines are group medians). 
KCNJ11 cases are shown in dark gray (circles are individuals and lines are group medians).
Figure 2 Incremental glucose (blue solid line), insulin (red solid line) and glucagon (black broken line) in controls without 
diabetes and sulfonylurea- treated KCNJ11 cases with carbohydrate (upper panel) and protein/fat (lower panel) meals. Values 
shown are medians.
vs 19.7 (17.7–21.2) mmol/L, p=0.009) (figure 1A). In 
controls, glucose values were tightly regulated after 
the two meals (figures 1A and 2 and online supple-
mentary figure S1) (glucose tAUC after carbohydrate 
21.4 (19.3–25.7) mmol/L and after protein/fat 19.7 
(17.7–21.2) mmol/L, p=0.08). In KCNJ11 cases glucose 
levels were much higher after carbohydrate (glucose 
tAUC after carbohydrate 58.1 (45.9–62.0) mmol/L than 
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Figure 3 Glucagon total area under the curve (AUC) over 
4 hours. Controls are shown in light gray (diamonds are 
individuals and lines are group medians). KCNJ11 cases are 
shown in dark gray (circles are individuals and lines are group 
medians).
after protein/fat 31.3 (23.5–35.3) mmol/L, p=0.04) 
(figures 1A and 2 and online supplementary figure S1). 
Similar trends were seen using iAUC (online supplemen-
tary table 1).
In cases, glucose increased 6.3 mmol/L from base-
line in the first hour after carbohydrate and remained 
2.6 mmol/L above baseline at 4 hours. In contrast, after 
protein/fat, glucose fell reaching median 5.9 mmol/L 
below baseline at 4 hours (figure 2 and online supple-
mentary figure S1). Despite falling glucose after protein/
fat, no cases became hypoglycemic in the 4- hour study 
period: the lowest glucose value recorded was 4.4 mmol/L. 
Consistent with these glucose profiles, all cases and 
controls had the lowest possible scores at all time points 
when screened for symptoms of hypoglycemia, indicating 
an absence of subjective symptoms. There were also no 
objective symptoms of hypoglycemia during observation 
of participants by the study nurse and doctor.
different glycemic responses to meals were explained by 
different patterns of insulin secretion in KCNJ11 cases versus 
controls
Insulin secretion was higher in controls versus cases after 
the carbohydrate meal (insulin tAUC0- 4h 727 (409–1302) 
vs tAUC0- 4h 327 (175–647) pmol/L, p=0.03) but not after 
the protein/fat meal (insulin tAUC0- 4h 335 (241–722) vs 
378 (228–508) pmol/L, p=0.60) (figure 1B). In controls 
insulin secretion was greatly increased after the carbohy-
drate meal compared with the protein/fat meal (insulin 
tAUC0- 4h 727 (409–1302) vs 335 (241–722) pmol/L, 
p=0.04), but in the KCNJ11 cases insulin secretion was 
similar with the two meals (insulin tAUC0- 4h 327 (175–
647) after carbohydrate and 378 (228–508) pmol/L after 
protein/fat, p=0.50) (figures 1B and 2 and online supple-
mentary figure S1).
The same pattern was observed using iAUC (online 
supplementary table 1) and when insulin secretion was 
adjusted for glucose (insulin tAUC/glucose tAUC)0-0.4h 
in controls after carbohydrate versus protein/fat, 33.9 
(19.6–50.8) vs 18.9 (11.4–36.2), p=0.04, and in KCNJ11 
cases 6.2 (2.9–14.1) vs 11.7 (9.7–14.4), p=0.08 (online 
supplementary figure S2). These results are consistent 
with KCNJ11 cases not being glucose responsive, in 
contrast to controls without diabetes.
glucagon secretion is increased in response to protein/fat 
compared with carbohydrate in both cases and controls
Both controls and cases had higher glucagon secretion 
after protein/fat than carbohydrate (glucagon tAUC0- 4h 
in controls 32.5 (13.8–37.9) vs 7.2 (5.6–11.2) pmol/L, 
p=0.04, and in cases 17.4 (7.8–28.3) vs 6.1 (5.7–8.9) pmol/L, 
p=0.04) (figures 2 and 3 and online supplementary figure 
S1). This is consistent with an alpha cell response to amino 
acids and/or fatty acids in both groups.
Paracetamol profiles indicate similar rates of gastric 
emptying
Paracetamol concentration- time curves are shownin 
online supplementary figure S3. Emptying index (tmax/
pmax) and tAUC were similar between controls versus cases 
(tmax/pmax for carbohydrate 0.03 vs 0.05, p=0.46, and for 
protein/fat 0.04 vs 0.03, p=0.60, paracetamol tAUC0- 4h for 
carbohydrate 30.5 (21.9–55.5) vs 28.5 (18.5–44.4) mg/L, 
p=0.75, and for protein/fat 28.4 (24.4–46.7) vs 36.5 
(13.6–40.4) mg/L, p=0.92). Emptying index and tAUC 
were also similar between meals in controls (emptying 
index p=0.89, tAUC0- 4h, p=0.45) and in cases (emptying 
index p=0.50, tAUC0- 4h, p=0.92).
effects of su independent of food in KCNJ11 cases
Glucose fell to a similar extent after both SU only (no food) 
and protein/fat (online supplementary figures S4 and 
S5) and there was no difference in overall glucose levels 
(glucose tAUC0- 4h with no food 34.6 (28.7–42.8) mmol/L 
and after protein/fat 31.3 (23.5–35.3) mmol/L, p=0.22). 
In contrast, glucose levels were lower after SU only versus 
carbohydrate (glucose tAUC0- 4h with no food 34.6 (28.7–
42.8) vs 58.1 (45.9–62.0) mmol/L, p=0.04). The same 
trends were seen using glucose iAUC (online supplemen-
tary table 1).
Insulin secretion in the 4 hours after a meal was higher 
after both carbohydrate versus SU only (insulin tAUC0- 4h 
327 (175–647) vs 174 (129–280) pmol/L, p=0.04, and 
insulin iAUC 205 (104–480) vs 39 (13–101) pmol/L, 
p=0.04). There was also a trend towards higher insulin 
secretion after protein/fat versus SU only (insulin 
tAUC0- 4h 378 (228–508) vs 174 (129–280) pmol/L, p=0.08, 
and insulin iAUC 183 (109–316) vs 39 (13–101) pmol/L, 
p=0.04) (online supplementary figures S4 and S5). This 
supports a key role for food in triggering insulin release 
in the context of SU- treated KCNJ11 PNDM.
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Glucagon secretion was similar in the absence of food 
versus carbohydrate (glucagon tAUC0- 4h 6.0 (5.6–18.7) 
vs 6.1 (5.7–8.9) pmol/L, p=0.69, and glucagon iAUC 0.2 
(−0.2 to 1.9) vs 0.5 (0.1–1.2) pmol/L, p=0.50) despite 
very different glucose levels. In contrast, there was a 
trend towards lower glucagon secretion in the absence of 
food versus protein/fat (glucagon tAUC0- 4h 6.0 (5.6–18.7) 
vs 17.4 (7.8–28.3) pmol/L, p=0.22, and glucagon iAUC0- 4h 
0.20 (–0.2 to 1.9) vs 11.8 (2.2–16.7) pmol/L, p=0.04).
The rate of gastric emptying did not change with 
SU only in comparison to the two meals (paracetamol 
tAUC0- 4h with no food 34.6 (20.0–43.4) mg/L and with 
carbohydrate 28.5 (18.5–44.4) mg/L, p=0.89, parac-
etamol tAUC0- 4h with no food 34.6 (20.0–43.4) mg/L and 
with protein/fat 36.5 (13.6–40.4) mg/L, p=0.69).
dIsCussIOn/COnClusIOns
We have shown clear differences in glucose levels and 
insulin secretion after carbohydrate and protein/fat 
meals between controls without diabetes and individuals 
with SU- treated KCNJ11 PNDM.
While controls show tightly regulated glucose levels 
after meals, individuals with KCNJ11 PNDM have lower 
glucose after protein/fat versus carbohydrate. These 
different glucose profiles have clinical implications in 
terms of dietary advice offered to patients with SU- treated 
KCNJ11 PNDM. In this specific type of diabetes, patients 
should avoid meals or diets completely lacking carbohy-
drate since blood glucose is likely to fall postprandially 
in the context of a protein/fat meal. Furthermore, they 
should avoid missing meals after taking SU, as we also 
observed a fall in glucose with SU in the absence of food.
In addition to the practical implications, our data may 
provide a mechanistic explanation as to why patients with 
SU- treated KCNJ11 PNDM report hypoglycemia after 
protein/fat- rich meals. Insulin secretion after protein/
fat and carbohydrate is similar in affected individuals 
despite very different glucose profiles. This supports 
insensitivity to glucose and lack of moderation of incretin 
and amino acid/fatty acid- stimulated insulin secretion 
after a protein/fat meal. Consistent with this is human 
and rodent data from previous studies demonstrating 
non- KATP- driven insulin secretion in the presence of 
normal or low glucose. Humans with congenital hyperin-
sulinism caused by recessively inherited inactivating (loss 
of function) KATP channel mutations have insensitivity to 
leucine, which acts through KATP pathways, but sensitivity 
to glutamine, which acts independently of ATP to drive 
insulin secretion and hypoglycemia after protein- rich 
meals.20 Furthermore, SUR1 knockout mice are eugly-
cemic but show amino acid- stimulated insulin secretion 
which is particularly sensitive to glutamine.21
The pattern of the insulin response to the different 
meals in SU- treated KCNJ11 PNDM contrasts with the 
pattern in controls without diabetes where carbohy-
drate, acting through the classical ATP pathway, elicits 
a far greater insulin response than protein/fat and is 
quickly ‘switched off’ in response to normalization of 
blood glucose. It also contrasts with the response in indi-
viduals with type 1 diabetes on intensive insulin therapy, 
who show rises in postprandial glucose 3–5 hours after a 
high- protein/fat meal and in whom protein is protective 
against hypoglycemia.22
Our results are consistent with the previously hypoth-
esized mechanism of insulin secretion in patients with 
SU- treated KCNJ11 PNDM. Pearson et al reported a large 
reduction in insulin secretion following intravenous 
glucose versus oral glucose supporting predominance 
of non- KATP- mediated amplifying pathways over the clas-
sical ATP pathway in these patients.4 The small amount 
of insulin secretion and fall in glucose we observed in 
the absence of food contrasts with the idea of a purely 
permissive action of SUs on the beta cell,4 although our 
experimental design differed from previous physiological 
studies limiting direct comparison. The very high doses 
of SU used to treat KCNJ11 PNDM do not result in severe 
hypoglycemia highlighting the possibility of a different 
pharmacological mechanism to the direct effects on the 
KATP channel seen in T2D. Further research is needed to 
improve understanding of the mechanism of SU action 
in KCNJ11 PNDM.
In our study, glucagon secretion was higher after 
protein/fat versus carbohydrate in both cases with 
KCNJ11 PNDM and controls without diabetes, consis-
tent with the previously described stimulatory effect of 
amino acids on alpha cells.17 We did not test the glucose 
responsiveness of alpha cells in this study as all individ-
uals remained euglycemic throughout. However, rodent 
models suggest defective glucagon secretion may occur 
in the presence of KATP channel mutations. Specifically, 
SUR1 knockout mice show an alpha cell secretory defect 
at low levels of glucose,23 KCNJ11 knockout mice exhibit 
defective glucagon secretion due to an impaired brain 
response to hypoglycemia,24 and intracerebroventric-
ular perfusion of KATP channels with SU in conscious 
rats reduces glucagon responses to hypoglycemia.25 In 
humans, the research and anecdotal clinical evidence 
to date suggests that these patients are protected from 
severe hypoglycemia, but the mechanisms of this remain 
unknown and future research will investigate in detail the 
counter- regulatory response to hypoglycemia in people 
with KCNJ11 mutations at the level of the alpha cell 
and the brain as previously described in the context of 
glucokinase mutations.26
Our study has important strengths. To our knowledge, 
it is the first study to assess the impact of different food 
types on glucose levels and insulin and glucagon secre-
tion in people with KCNJ11 PNDM, and to compare 
this with data from controls without diabetes. Previous 
research has been limited to assessment of insulin secre-
tion following oral and intravenous glucose tolerance 
tests in small groups of affected individuals without a 
control group for comparison.4 5
Our study has some limitations. First, the numbers 
of cases and controls are small and only two mutations 
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in the KCNJ11 gene (R201H and R201C) were studied, 
reflecting the rarity of the disease. However, these are 
the most common mutations and both impact ATP 
binding. Second, as the individuals in our study did not 
have glucose levels in the hypoglycemic range, we were 
unable to assess the alpha cell response in the presence 
of low glucose as discussed above. Finally, the study was 
only done in adults, which may limit the generalizability 
of the findings, particularly for patients in the pediatric 
age range. Additional studies in children with SU- treated 
KCNJ11 PNDM will be required to investigate the beta 
and alpha cell responses to carbohydrate and protein/
fat and to establish whether these responses differ from 
those observed in adults.
In conclusion, we have shown that individuals with 
SU- treated KCNJ11 PNDM produce similar levels of 
insulin in response to both carbohydrate and protein/
fat meals despite carbohydrate meals resulting in much 
higher glucose levels and protein/fat meals being char-
acterized by relatively low glucose levels. This suggests 
an apparent inability to modulate insulin secretion 
in response to both higher (carbohydrate) and lower 
(protein/fat) glucose levels, which is consistent with 
a dependence on non- KATP- channel pathways for 
insulin secretion. Our findings may provide a mecha-
nistic explanation for the postprandial hypoglycemia 
reported by patients with KCNJ11 PNDM. Furthermore, 
glucose levels can fall with SUs in the absence of food. 
We would therefore recommend that affected individ-
uals avoid missed meals or meals lacking carbohydrate 
while on SU treatment. Finally, our data highlight 
the utility of KCNJ11 PNDM as a model for studying 
non- KATP- mediated pathways of insulin secretion and 
demonstrate the predominance of the classical ATP 
pathway in the non- diabetic state.
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